VYNE Therapeutics Inc. develops differentiated therapies for chronic inflammatory and immune-mediated conditions through proprietary BET inhibitor programs. News about VYNE centers on its InhiBET™ platform, Repibresib gel for nonsegmental vitiligo, and VYN202, an oral BD2-selective BET inhibitor being evaluated for immune-mediated diseases.
Company updates also cover clinical and regulatory communications, nonclinical toxicology work, quarterly operating results, cost-control actions, capital-structure matters, governance developments, and shareholder voting matters tied to its Nasdaq-listed common stock.
VYNE Therapeutics Inc. (Nasdaq: VYNE) announced that CEO David Domzalski will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference from December 1-3, 2020. The chat will be accessible to institutional clients starting December 1 via Piper Sandler’s event portal. VYNE, formed by the merger of Menlo Therapeutics and Foamix Pharmaceuticals in March 2020, specializes in innovative dermatological therapies. The company has received FDA approval for its products AMZEEQ® and ZILXI™, marking significant advancements in topical treatment options.
VYNE Therapeutics Inc. reported its third-quarter financial results for the period ending September 30, 2020. The company generated revenues of $3.3 million, primarily from AMZEEQ, marking a notable increase from the previous year. The launch of ZILXI on October 1 has enhanced its dermatology portfolio. The company experienced a net loss of $24.7 million but anticipates that its cash reserves of $76.9 million will sustain operations through 2021. Overall, prescription volumes for AMZEEQ have surged 52% in Q3, reflecting a recovery in the acne market.
VYNE Therapeutics Inc. (Nasdaq: VYNE) is set to report its third-quarter financial results for the period ending September 30, 2020, on November 5, 2020, before market hours. A conference call will be held at 8:30 a.m. ET to discuss the results and provide updates. VYNE specializes in developing innovative dermatological therapies, having received FDA approvals for AMZEEQ® and ZILXI™, both minocycline topical foams. The company emphasizes its commitment to improving patient lives through proprietary technologies.
VYNE Therapeutics announced its novel ZILXI™ (minocycline) topical foam has gained coverage from Express Scripts, effective October 2, 2020. The FDA approved ZILXI in May 2020, making it the first minocycline product for treating rosacea in adults. The annual cost of ZILXI is $485 per 30-gram canister. This coverage represents access for millions of patients in the U.S. and is a significant milestone for VYNE, enhancing treatment options for those with rosacea.
VYNE Therapeutics announced that its FDA-approved ZILXI (minocycline) topical foam, 1.5%, will be covered by Express Scripts effective October 2, 2020. This coverage will expand access to millions of additional patients in the U.S. ZILXI is the first minocycline product approved for treating inflammatory lesions of rosacea in adults. The annual list price is $485 per 30-gram canister. The company emphasizes ZILXI's innovative formulation, which minimizes systemic side effects by delivering the medication in a topical form, leveraging its proprietary Molecule Stabilizing Technology (MST™).
VYNE Therapeutics Inc. (Nasdaq: VYNE) announced the availability of its new product, ZILXI™ (minocycline) topical foam, 1.5%, for treating inflammatory lesions of rosacea, starting October 1, 2020. This is the first minocycline product approved by the FDA for rosacea. ZILXI is priced at $485 per 30-gram canister and the company aims to ensure broad patient access through commercial insurer contracts. VYNE is employing a multi-channel marketing strategy and utilizing their sales force to target rosacea physicians effectively.